Seeking Alpha

KORU Medical Systems projects 20%–22% revenue growth for 2025 while advancing oncology and international expansion

Full year 2025 revenue guidance was raised to "$40.5 million to $41 million, representing a 20% to 22% growth, an increase from our prior range of $39.5 million to $40.5 million." Gross margin ...
Seeking Alpha

KORU Medical: Too Early To Turn Bullish

KORU Medical's revenue came in below expectations for the past three quarters. But I am of the view that KRMD can still meet its goal of realizing a +20% top line CAGR for the FY 2022-2026 period.
Nasdaq

KORU Medical Systems Signs a Clinical Supply Agreement for Phase 3 Trial with Leading Pharma Partner Using Custom Device for a Novel Subcutaneous Immunoglobulin

MAHWAH, N.J.--(BUSINESS WIRE)-- KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and ...
Business Wire

KORU Medical Systems, Inc. Announces Development Agreement for Next-generation Subcutaneous Immunoglobulin Infusion System

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and ...